Investigational Drug Details
Drug ID: | D204 |
Drug Name: | Lamivudine |
Synonyms: | |
Type: | small molecule |
DrugBank ID: | DB00709 |
DrugBank Description: | A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV). |
PubChem ID: | 60825 |
CasNo: | 134678-17-4 |
Repositioning for NAFLD: | Yes |
SMILES: | NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1 |
Structure: |
|
InChiKey: | JTEGQNOMFQHVDC-NKWVEPMBSA-N |
Molecular Weight: | 229.256 |
DrugBank Targets: | Reverse transcriptase/RNaseH; DNA; Protein P |
DrugBank MoA: | Lamivudine is a synthetic nucleoside analogue and is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP). This nucleoside analogue is incorporated into viral DNA by HIV reverse transcriptase and HBV polymerase, resulting in DNA chain termination. |
DrugBank Pharmacology: | Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV) to disrupt viral DNA synthesis. When phosphorylated, lamivudine can form active metabolites that compete for incorporation into viral DNA. Via DNA incorporation, lamivudine metabolites competitively inhibit the activity of the HIV reverse transcriptase enzyme and act as a chain terminator of DNA synthesis. Due to the lack of a 3'-OH group, incorporated nucleoside analogues prevent the formation of a 5' to 3' phosphodiester linkage that is essential for DNA chain elongation. |
DrugBank Indication: | For the treatment of HIV infection and chronic hepatitis B (HBV). |
Targets: | |
Therapeutic Category: | |
Clinical Trial Progress: | |
Latest Progress: |

Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
---|
Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
---|
Article ID | PMID | Source | Title |
---|